Competitive landscape · Comparables

Two of our closest comparables have been acquired.

The PTSD and CBD-pharmaceutical adjacencies have produced two recent monetization events: Jazz acquired GW Pharmaceuticals for $7.2B, and Otsuka acquired Transcend Therapeutics for $1.225B. Both bracket exactly what Ananda is building.

$8.4B

Total comp value

Mar 2026

Most recent

6 tracked

Active programs

2 mono

PTSD approvals / 25y

505(b)(1)

Our pathway

Recent monetization · Acquired comparables

The market has paid for this kind of asset.

Acquired · May 2021

GW Pharmaceuticals

$7.2B

Asset: Epidiolex® (cannabidiol oral solution)
Indication: Lennox-Gastaut · Dravet · TSC-associated seizures
Acquirer: Jazz Pharmaceuticals
Stage at deal: Approved (FDA 2018, EMA 2019)
Structure: Cash + stock; ~50/50
Revenue: $510M (2020) · $828M (2022)

Why it matters

CBD as a pharmaceutical product: the first cannabis-derived FDA-approved drug, sold by Jazz at >$1B/yr — narrow orphan indications. The dosing burden is what Liquid Structure™ is engineered to remove for adult, take-home indications.

A CBD oral solution can clear the FDA and reach blockbuster revenue. The adult psychiatric and adjacency indications remain open.

Acquired · March 27, 2026

Transcend Therapeutics

$1.225B

Asset: TSND-201 (methylone)
Indication: PTSD
Acquirer: Otsuka Pharmaceutical
Stage at deal: Phase 2 complete · Phase 3 underway
Structure: $700M upfront + up to $525M in milestones

Why it matters

A single Phase 2 readout in PTSD attracted a $700M upfront from Otsuka — pre-Phase 3, pre-NDA. This is the cleanest recent read on what a strategic will pay for derisked Phase 2 PTSD efficacy.

Closest comparable: PTSD asset, similar stage, monetized in the last 12 months.

$700M

Otsuka upfront for Phase 2 PTSD

Transcend · Mar 2026

$7.2B

Jazz–GW (cash + stock)

CBD precedent · 2021

$510M

Epidiolex Year-2 net sales

CBD-as-pharma proof

25 yrs

Since last PTSD monotherapy

Paroxetine · 2001

Active landscape · PTSD & adjacencies

What we're actually running against.

Otsuka · Lundbeck

Brexpiprazole (Rexulti®) + sertraline

Cleared

Mechanism: Atypical antipsychotic (5-HT₁ₐ partial agonist) adjunct to SSRI
Stage: CRL · 2024
Indication: Adjunctive PTSD

FDA declined to approve the brexpiprazole-plus-sertraline adjunct for PTSD.

Pfizer · GSK (generic)

Sertraline · paroxetine

Incumbent

Mechanism: SSRIs
Stage: FDA-approved · 1999 / 2001
Indication: PTSD (mono)

Standard of care by default, not by efficacy: ~30% response, weeks to onset, sexual dysfunction.

Neuphoria (fmr Bionomics) · Merck

BNC210 (iclepertin)

Trailing

Mechanism: α7 nicotinic ACh receptor negative allosteric modulator
Stage: Phase 2/3
Indication: PTSD · Social Anxiety

Oral, non-sedating, novel mechanism. Phase 2 PTSD readout (ATTUNE) missed primary on CAPS-5 in 2023.

Transcend · Otsuka (acquired)

TSND-201 (methylone)

High signal

Mechanism: Rapid-acting serotonin releaser; non-hallucinogenic MDMA analog
Stage: Phase 3
Indication: PTSD

Strong Phase 2 — positive CAPS-5 with single-dose, weekly-cadence regimen. Now Otsuka-funded.

MindMed

MM120 (LSD)

Watch

Mechanism: Serotonergic psychedelic (5-HT₂ₐ agonist)
Stage: Phase 3
Indication: GAD · MDD (PTSD signal)

Breakthrough designation 2024. Single-dose model, in-clinic supervision required. Schedule I, REMS-heavy.

Lykos (fmr MAPS PBC)

MDMA-AT (midomafetamine)

Cleared

Mechanism: Empathogen + manualized therapy
Stage: CRL · Aug 2024
Indication: PTSD

FDA Complete Response Letter cited durability and trial-blinding concerns. New Phase 3 required.

Capability matrix

Eight requirements. One asset meets them all.

Capability	Nantheia™ Ananda	TSND-201 Otsuka	MM120 MindMed	BNC210 Neuphoria	SSRIs Generic
Take-home oral dosing	●	●	○	●	●
No DEA scheduling burden	●	○	○	●	●
Non-psychoactive	●	◐	○	●	●
Composition-of-matter IP (drug + delivery)	●	●	●	●	○
4+ year ambient shelf life	●	◐	◐	●	●
Multi-mechanistic (CB1/2, 5-HT, GABA, vanilloid)	●	◐	◐	○	○
No black-box / class warnings	●	◐	○	◐	○
Pediatric pathway open	●	○	○	○	◐

●Meets◐Partial○Does not meet

Capability framing per Ananda product spec; competitor data per FDA labels & published trial protocols.

Why this lane

The white space is the boring drug.

Every active competitor is solving the wrong problem. Psychedelics fight the FDA on durability and blinding; SSRIs are 25-year-old generics. Ananda's lane is the unglamorous, defensible one — a take-home oral capsule on a standard regulatory path.

Regulatory

Standard 505(b)(1) NDA — no novel review framework required.

Schedule

No DEA scheduling. Prescribed and dispensed like any oral capsule.

Setting

Take-home. No in-clinic supervision, no certified-therapist requirement.

Safety

No black box, no abuse liability, no metabolic warnings, no QT signal.

Defensibility

Composition-of-matter on Liquid Structure platform — applies across indications.

Optionality

1 platform → 6 indications. Each readout re-prices the rest.

Sources: Jazz Pharmaceuticals 8-K (May 5, 2021); Otsuka & Transcend Therapeutics joint press release (Mar 27, 2026); FDA drug labels; published trial protocols.